🚨 A single IV injection permanently lowered LDL cholesterol by 62%. No daily pills. No biweekly injections. No adherence problem. One shot. Done. But this is not science fiction. This is published data in the New England Journal of Medicine. I am a cardiologist who has watched patients fail cholesterol therapy not because the drugs don't work, but because life gets in the way. Missed doses. Insurance gaps. Injection fatigue. That is the adherence problem medicine has never solved. Until now. 💓 Here is what the science actually says. The HEART-2 Trial (VERVE-102) published Phase 1 results on May 25, 2026. A single intravenous infusion of VERVE-102 used base-editing technology to permanently inactivate the PCSK9 gene inside liver cells. ✅ HEART-2 (VERVE-102): LDL cholesterol reduced 62% from a single dose. That is not a typo. One treatment. Permanent gene-level change. 🔬 Here is the mechanism and why it matters. PCSK9 is the protein that destroys LDL receptors in your liver. When PCSK9 is active, your liver cannot clear LDL from your blood efficiently. Base editing rewrites a single letter in the PCSK9 gene at the DNA level. The liver cells stop producing PCSK9. LDL receptors stay active. LDL drops. This mimics what nature already proved works. Humans born with natural PCSK9 loss-of-function mutations carry lifetime LDL levels that run dramatically lower than average, and they show 88% reduction in coronary artery disease risk over a lifetime. VERVE-102 engineers that same protection into adults who were not born with it. ⚠️ This is still Phase 1 data. Phase 1 trials establish safety and dosing. The 62% LDL reduction is real and it is remarkable. Long-term cardiovascular outcomes data is not yet available. Off-target editing effects require continued surveillance. This therapy is not approved and is not in clinical use today. But the signal is strong enough that every cardiologist needs to pay attention right now. 🩺 Why PCSK9 Is The Right Target. PCSK9 inhibitors already have the cardiovascular outcome data. FOURIER (evolocumab) showed 15% reduction in major cardiovascular events. ODYSSEY OUTCOMES (alirocumab) showed 15% reduction in cardiovascular death, heart attack, and stroke. The biology is validated. The target is proven. VERVE-102 goes one step further and eliminates the target permanently at the genetic level. A patient who takes VERVE-102 once does not need to remember a pill tomorrow. They do not need a refill. They do not need a prior authorization renewal. They do not need a nurse to administer a monthly injection. That is the difference between 62% LDL reduction maintained for a lifetime and 30% LDL reduction that disappears when adherence breaks down. ❤️ Bottom line: This is not a supplement. It is not a biohack. It is peer-reviewed, gene-level cardiovascular medicine published in the New England Journal of Medicine. Natural PCSK9 loss-of-function mutations reduce lifetime coronary artery disease risk by 88%. VERVE-102 engineers that same biological state with a single IV dose and produced 62% LDL reduction in Phase 1. The question is no longer whether gene editing can lower LDL. The question is how fast we can get outcome data and get this therapy to the patients who need it most. Watch HEART-2 closely. This trial could redefine preventive cardiology for the next generation. #Cardiology #HeartDisease #HeartHealth #CardiovascularHealth #CRISPR #GeneEditing #PCSK9 #LDLCholesterol #PreventiveCardiology #CardiovascularMedicine

With the intense focus on cortisol, has anyone notified Health and Human Services that we are in the midst of a Cushing syndrome epidemic? Buffalo humps and abdominal striae as far as the eye can see!!!

Fascinating

Retatrutide data are in…almost unbelievable efficacy. We are truly pushing into results previously only seen in bariatric surgery. Does this mean everyone should take it? Absolutely not. But for the right patient could be game changing and life saving.

Retatrutide, a triple receptor drug for GLP-1, GIP, and glucagon, is the most powerful weight loss drug yet. A significant issue is too much weight loss among the trial participants. New randomized trial results announced today with 28% body weight loss. gift link nytimes.com/2026/05/21/scien…

Exercise is critical for health and longevity—CRITICAL. But for weight loss, diet matters more. Don’t wait to get started just because you can’t exercise. Change your diet now.
Add exercise when you can.

Would you judge someone for grabbing a fire extinguisher when a bucket of water couldn’t put out the fire? 
So why judge people using GLP‑1s?

There are endless diets: Mediterranean, low‑carb, carnivore, vegan. People argue about which one is “best” for weight loss. They all work — if you’re in a caloric deficit. None of them work — if you’re not.

I’m a trauma surgeon triple board-certified in general surgery, surgical critical care, and obesity medicine. I see the downstream effects of poor metabolic health every day and have struggled myself. Most conversation around this misses the point. Let’s talk about why.